Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma
- 1 September 2002
- journal article
- clinical trial
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 30 (6) , 367-373
- https://doi.org/10.1038/sj.bmt.1703652
Abstract
Bone Marrow Transplantation is a high quality, peer-reviewed journal covering all aspects of clinical and basic haemopoietic stem cell transplantation.Keywords
This publication has 48 references indexed in Scilit:
- High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusionsBlood, 2001
- Donor leukocyte infusions for multiple myelomaBone Marrow Transplantation, 2000
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATIONBritish Journal of Haematology, 1998
- Long-term follow-up after high-dose therapy for high-risk multiple myelomaBone Marrow Transplantation, 1998
- The Treatment of Multiple MyelomaNew England Journal of Medicine, 1994
- Metabolism and action of purine nucleoside analogsPharmacology & Therapeutics, 1991
- USE OF DNA RESTRICTION FRAGMENT LENGTH POLYMORPHISMS TO DOCUMENT MARROW ENGRAFTMENT AND MIXED HEMATOPOIETIC CHIMERISM FOLLOWING BONE MARROW TRANSPLANTATIONTransplantation, 1987
- HIGH-DOSE INTRAVENOUS MELPHALAN FOR PLASMA-CELL LEUKAEMIA AND MYELOMAThe Lancet, 1983
- CLINICAL MANIFESTATIONS OF GRAFT-VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONOR,STransplantation, 1974
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958